Controlled prospective studies are needed to clarify this issue. Background. Angiotensin-converting enzyme (ACE) inhibitors have the capability of decreasing left ventriKey words: ACE inhibitors; anaemia; erythrocular mass index (LVMI ) in chronic haemodialysis poietin; haemodialysis; hypertension; left ventricular (HD) patients. On the other hand, recent reports hypertrophy provide conflicting information regarding the impact of ACE inhibitors on responsiveness to recombinant human erythropoietin (rHuEpo), and there are no data about the effect of withdrawing ACE inhibitors both Introduction on rHuEpo response and LVMI in HD patients.
about the effect of withdrawing ACE inhibitors both Introduction on rHuEpo response and LVMI in HD patients.
Methods. ACE inhibitors were switched to another
The introduction of recombinant human erythropoieantihypertensive medication in 23 out of 68 patients in tin (rHuEpo) into clinical practice has been a very our HD unit who were receiving both rHuEpo and an important improvement for the management of anae-ACE inhibitor for more than 1 year. Blood pressure mia of end-stage renal disease ( ESRD) [1, 2] . However, at the pre-and post-dialysis phases, haematocrit levels the dose of rHuEpo required to correct anaemia varies and rHuEpo doses were determined at the end of the among the patients, and some can be unresponsive in first and of the third years, and the LVMI was deterspite of applying very high doses. The common causes mined at the end of the third year. Statistical analyses for inadequate response to rHuEpo are iron deficiency, were done in 15 patients in whom the study could be infection and inflammation, osteitis fibrosa, aluminium completed.
toxicity, folate or vitamin B12 deficiency, inadequate Results. The mean (±SD) haematocrit level was dialysis, and malnutrition [3, 4] . Nevertheless, the increased from 26.3±6.4% to 29.8±6.3% at the first reason for incomplete response to rHuEpo is not year (P<0.05), and to 29.4±6.5% at the third year completely clear, as some patients lacking these factors (P<0.05 vs before), while the mean dose of rHuEpo can also be unresponsive to rHuEpo. was decreased from 208.3±99.0 UI/kg/week to Left ventricular hypertrophy (LVH ) is quite frequent 141.0±91.8 at the first year (P=0.01), and to in chronic haemodialysis (HD) patients, and hyperten-141.4±81.0 at the third year (P=0.01 vs before).
sion and anaemia are the major predictors of this Administration of rHuEpo had been stopped in two complication [5] [6] [7] . Angiotensin-converting enzyme patients at the end of the first year. The mean blood (ACE) inhibitors are shown to induce regression of pressure level and the mean LVMI were not changed LVH in patients with essential hypertension [8, 9] , (P>0.05 vs before). There were no significant changes chronic renal failure [10] , and ESRD [11] . In addition, in dialysis parameters, iron status, plasma renin activithypertension in HD patients has been shown to be ies, and levels of aldosterone, intact parathyroid horsuccessfully treated by this class of drugs without any mone, aluminum and erythropoietin. significant untoward event [12] . Accordingly, ACE Conclusion. The findings of this small uncontrolled inhibitors seem to be drugs of choice for the treatment study indicate that withdrawl of ACE inhibitors in of both LVH and hypertension in chronic HD patients. hypertensive chronic HD patients receiving rHuEpo
In experimental and clinical studies, ACE inhibitors may result in an increase in haematocrit level, and a have been shown to cause anaemia [13, 14] . Hence, an decrease in dose of rHuEpo without any significant initial concern that ACE inhibitors would worsen the changes in the blood pressure level and LVMI.
anaemia of ESRD came up. More recent reports, however, provide conflicting information about this issue: some reports suggested that there was neither an
The impact of withdrawing ACE inhibitors on rHuEpo responsiveness 1913 cular end-systolic diameter (LVESD), and left ventricular crit by ACE inhibitors [15] [16] [17] , whereas the others end-diastolic diameter (LVEDD). Left ventricular fractional concluded that this class of drugs did inhibit the action shortening (FS ) was derived from the formula of of rHuEpo [18, 19] . As far as our knowledge is concerned, there is no 
Subjects and methods
before, and at the end of the first and third years after weaning were used. To evaluate the data, Wilcoxon matchedTwenty-three out of 68 patients in our HD unit were being pairs signed-ranks test was used. Unless stated otherwise, all administered both rHuEpo and an ACE inhibitor for more data were reported as the mean±SD. Two-tailed P values than a year (i.e. enalapril 10-40 mg/day, 19 patients; captop-<0.05 were considered statistically significant. ril 25-75 mg/day, three patients; and perindopril 2 mg/day, one patient). After a 3-month period for the basal evaluResults ations, ACE inhibitor was switched to another antihypertensive medication in all patients (i.e. amlodipine 5-10 mg/day in 12 patients, felodipine 5 mg/day in six patients, and Demographic features of the patients and the relevant doxazosin 4-8 mg/day in five patients). During the first year laboratory data are shown in Table 1 . There were 10 of the study, four patients received renal allografts, three men and 5 women, and the mean age was 33.7±8.4 started continuous ambulatory peritoneal dialysis, and one years (range 18-50 years). Causes of ESRD were patient died from an untreatable pulmonary infection. Hence, chronic tubulointerstitial nephritis in six patients, those eight patients were excluded from the study. None of chronic glomerulonephritis in five patients, and the remaining 15 patients had haematological diseases, active unknown in four patients. The mean duration under untreated infections, malignancies or other causes of inflammation.
HD treatment at the beginning of the study was All patients were dialysed with a single-use cellulosic 68.5±25.7 months (range 24-120, median 60 months). cuprophane capillary membrane three times a week (12 Mean Kt/V(urea) value under an ACE inhibitor was h/week), using bicarbonate dialysate bath. During HD, all 1.17±0.18, and those at 1 and 3 years after the weaning patients were ultrafiltrated to achieve their estimated dry of the drug were 1.18±0.22 and 1.23±0.26, respectweight. Ultrafiltration volume (as per cent of body weight), ively (P>0.05 vs before).
and Kt/V(urea) values according to Daugirdas [20] were Nine patients (60%) were resistant to rHuEpo at the calculated monthly. Blood pressure measurements were done baseline. Haematocrit levels in 13 patients (86.7%) before and after each HD session. Administration of rHuEpo started to increase 3 months after the withdrawl of was done through subcutaneous route at the end of the HD ACE inhibitor. The mean haematocrit level was session, and the doses were adjusted monthly. A patient was defined as being resistant to rHuEpo if a haematocrit level increased from 26.3±6.4% to 29.8±6.3% at the first of 30% could not be achieved despite applying a rHuEpo year (P<0.05), and to 29.4±6.5% at the third year dose above 200 UI/kg/week [18] . All patients were given (P<0.05 vs before). Dose of rHuEpo was decreased in oral iron and calcitriol. Intravenous iron infusion was used 11 patients (73.3%) after the substitution. The mean as necessary [3] . dose of rHuEpo was decreased from 208.3±99.0 The following laboratory evaluations were done in all UI/kg/week to 141.0±91.8 (P=0.01) at the first year, patients: haematocrit and routine biochemistry (monthly); and to 141.4±81.0 (P=0.01 vs before) at the third transferrin saturation, and ferritin (every 3 months); vitamin year. Moreover, rHuEpo had been stopped in two B12, folate, intact parathyroid hormone (iPTH ), and alumipatients at the end of the first year. num (every 6 months); and plasma renin activity, aldosterone, There were no significant changes with regard to and erythropoietin (at the end of the first and third years).
Blood samples for the evaluations were taken immediately body weight, ultrafiltration volume, transferrin saturaafter the HD session.
tion, ferritin, vitamin B12, folate, iPTH and aluminum, Two-dimensional and M-mode echocardiography were either at the end of the first or of the third years performed just before, and 3 years after, the withdrawing of (P>0.05 vs before). In addition, plasma renin activities, the ACE inhibitor, using Hewlett Packard Sonos 1000, with aldosterone, and erythropoietin levels were not a 2.5-MHz transducer. All patients were examined in the left changed after the withdrawl of ACE inhibitor (P>0.05 lateral decubitus position by a single experienced echocardi-vs before).
ographer, who was blind to the results of the other study Blood pressure was well controlled in 12 patients at parameters evaluated. All measurements were made accordthe baseline, and no patients exhibited aggravation of ing to the American Society of Echocardiography guidelines hypertension after the ACE inhibitors were stopped. [21] . M-mode measurements included interventricular septal thickness, left ventricular posterior wall thickness, left ventri-Similarly, all 13 patients having LVH at the baseline still exhibited LVH at the end of the study. The mean would be opposite to their desirable effects on LVH.
In the present study, LVMI was not increased 3 years LVMI at the end of the third year (241.8±71.0 g/m2) was the same as that at the beginning after the withdrawl of ACE inhibitor, probably as a consequence of the better control of anaemia [23] . (236.7±57.3 g/m2), (P>0.05) ( Table 2 ). The mean blood pressure levels both at the pre-dialysis and post-However, it may be speculated that if the ACE inhibdialysis phases were not changed after the withdrawl itors had been continued and the haematocrit had been of ACE inhibitor (P>0.05 vs before). On the other kept at the same level there would have been a further hand, both before and after discontinuing of the drug, reduction in LVMI. Controlled prospective studies are systolic blood pressure levels were found to be needed to clarify this point. decreased significantly after the HD session (P<0.05
In this study, either a dihydropyridine calcium antagvs pre-dialysis), whereas reductions in diastolic blood onist (amlodipine or felodipine) or a peripheral alpha pressure levels were not statistically significant 1-adrenergic antagonist (doxazosin) substituted the (P>0.05).
ACE inhibitor. Both of these classes of drugs may achieve regression of LVH [24, 25] . Moreover, there are no data about their negative effects on rHuEpo
Discussion
responsiveness. During the study period, blood pressure was kept at the same level without aggravation of hypertension in any patients, and LVMI remained Hypertension and anaemia are the major predictors of stable. However, the low number of patients included cardiovascular disease in patients with .
in the follow-up prevents us establishing definitive ACE inhibitors are shown to control hypertension conclusions about the long-term impact of antihypereffectively [12] , and to have the capability of decreasing tensive drugs, different from ACE inhibitors, on LVMI in patients with various diseases including rHuEpo responsiveness and LVMI. ESRD [8] [9] [10] [11] . On the other hand, negative implications of ACE inhibitors in erythropoiesis, if present, Participation of the renin-angiotensin system in The impact of withdrawing ACE inhibitors on rHuEpo responsiveness 1915 erythropoiesis has long been recognized. Angiotensin the first step in our hypertensive HD patients receiving rHuEpo. Secondly, some of our patients had either II directly stimulates erythropoietin production in vivo [26, 27] , and induces the growth of early erythroid low ferritin levels indicating that iron deficiency was present at least in part of our patients, or high iPTH progenitors in vitro [28] . ACE inhibitors and angiotensin II type 1 receptor antagonists have been shown levels, factors known to cause poor response to rHuEpo. However, these parameters were not changed to decrease erythropoietin levels in animals [27, 29] , in renal transplant recipients with or without post-during the study period, and the unique factor for a better response to rHuEpo was the weaning of the transplant erythrocytosis [30] [31] [32] , and in uraemic patients [33] . In addition production of interleukin-12 ACE inhibitor. Thirdly, it might be relevant to evaluate plasma renin activities, aldosterone, and erythropoietin [34] and levels of IGF-1 [32] , cytokines known to induce erythropoiesis, were shown to be reduced by levels by more sequential studies within the first year after substitution of the ACE inhibitors by other ACE inhibitors. Convenient with these observations, it has been demonstrated by several studies that both antihypertensive drugs. Although peripheral hormone levels do not necessarily reflect the exact activity at the ACE inhibitors and angiotensin II type 1 receptor antagonists might contribute to anaemia or to a tissue level, and renin-angiotensin system is affected by many factors, including salt and fluid intake, ultradecrease in haemoglobin/haematocrit levels in animals [13, 29] , in patients with chronic renal failure [35] , with filtration, and drugs in HD patients; such an attempt could allow for the explanation of the mechanisms renal allografts [30] [31] [32] , and in patients under HD treatment [14] . Moreover, it has been shown that the potentially involved in the recovery of rHuEpo responsiveness. Finally, neither the reason for incomuse of ACE inhibitors might result in an increase in rHuEpo dose to maintain the desired haematocrit plete response to rHuEpo, nor the mechanism for a better response after the withdrawing of the ACE levels in dialysis patients [18, 19, 36 ] . Nevertheless, there are some reports suggesting a poor response to rHuEpo inhibitors could be found in the present study.
Unfortunately, there is currently no study evaluating was not the case with ACE inhibitors [15] [16] [17] . This discrepancy among the reports may arise from the all probable factors participating in erythropoiesis or rHuEpo response in HD patients. We think that further different drug doses administrated [19] , from ACE gene polymorphism by which the renin-angiotensin studies especially evaluating the impact of various cytokines [28,34,37,38] would help to solve this issue. system activation may be different from patient to patient (so that inhibition may result in different con-
In conclusion, the withdrawl of ACE inhibitors in hypertensive chronic HD patients receiving rHuEpo sequence) [9] , or from other unknown mechanisms.
We have previously demonstrated in a cross-may result in an increase in haematocrit level and a decrease in dose of rHuEpo without any significant sectional study that ACE inhibitors may cause rHuEpo unresponsiveness in HD patients [18] . In the present changes in the blood pressure level and LVMI. We recommend that ACE inhibitors can be safely switched study, we have shown that at the end of the first year of the withdrawl of ACE inhibitor, haematocrit levels to another antihypertensive medication in HD patients if poor response to rHuEpo exists. However, as the were increased while rHuEpo doses were decreased, and that these findings were stable at the end of the present study is small and uncontrolled, the conclusions drawn need to be confirmed in a controlled prospectthird year. These results correlate with the results of a recent study done by Albitar et al. [19] , in which ive study. enalapril was shown to increase rHuEpo requirement in HD patients. In that study, the mean rHuEpo dose Acknowledgements. We are grateful to Ms Gü lseren Eden for her in patients given enalapril, showed a return to baseline technical assistance. values 4 months after discontinuing the drug. Although we could not demonstrate the exact mechanism for a better response to rHuEpo after discontinuing of the References ACE inhibitor, it seems different from the effects on endogenous erythropoietin levels since those at the
